Table 21 Top 10 pairs of drugs with their correlation with subtype 9 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Rupatadine | TG-100801 | − 0.85 | − 0.72 | − 0.61 | 1 | 1 | 8 |
L-690330 | Favipiravir | − 0.83 | − 0.65 | − 0.48 | 2 | 5 | 76 |
Rupatadine | Lidocaine | − 0.82 | − 0.72 | − 0.51 | 3 | 1 | 51 |
Rupatadine | MG-132 | − 0.82 | − 0.72 | − 0.61 | 4 | 1 | 9 |
Rupatadine | ICI-185,282 | − 0.81 | − 0.72 | − 0.52 | 5 | 1 | 35 |
Rupatadine | Telatinib | − 0.79 | − 0.72 | − 0.47 | 6 | 1 | 82 |
Rupatadine | Vidarabine | − 0.79 | − 0.72 | − 0.59 | 7 | 1 | 12 |
Garcinol | CL-218872 | − 0.78 | − 0.56 | − 0.49 | 8 | 24 | 60 |
Rupatadine | Bitopertin | − 0.77 | − 0.72 | − 0.48 | 9 | 1 | 71 |
Emtricitabine | Bitopertin | − 0.77 | − 0.65 | − 0.48 | 10 | 4 | 71 |